158 related articles for article (PubMed ID: 31729149)
41. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
Wang YC; Chen G; Chi GY
J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
[TBL] [Abstract][Full Text] [Related]
42. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
43. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
[TBL] [Abstract][Full Text] [Related]
44. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
45. Sample size estimation for stratified cluster randomization trial with survival endpoint.
Ni S; Zhong Z; Zhao Y; Chen F; Wu J; Yu H; Bai J
Stat Methods Med Res; 2024 May; 33(5):838-857. PubMed ID: 38549457
[TBL] [Abstract][Full Text] [Related]
46. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
47. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
Royston P; Parmar MK
BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
[TBL] [Abstract][Full Text] [Related]
48. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
49. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
50. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
[TBL] [Abstract][Full Text] [Related]
51. Introducing a new estimator and test for the weighted all-cause hazard ratio.
Ozga AK; Rauch G
BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
[TBL] [Abstract][Full Text] [Related]
52. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
Xu R; Mehrotra DV; Shaw PA
Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
[TBL] [Abstract][Full Text] [Related]
53. Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.
Wu J; Xiong X
Stat Biopharm Res; 2017; 9(1):35-43. PubMed ID: 28966722
[TBL] [Abstract][Full Text] [Related]
54. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
Potthoff RF; Halabi S
Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
[TBL] [Abstract][Full Text] [Related]
55. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
Shin W; Kang SH
J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
[TBL] [Abstract][Full Text] [Related]
56. Planning and analyzing adaptive group sequential survival trials.
Wassmer G
Biom J; 2006 Aug; 48(4):714-29. PubMed ID: 16972724
[TBL] [Abstract][Full Text] [Related]
57. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
58. Adaptive designs for the one-sample log-rank test.
Schmidt R; Faldum A; Kwiecien R
Biometrics; 2018 Jun; 74(2):529-537. PubMed ID: 28940387
[TBL] [Abstract][Full Text] [Related]
59. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
Ogungbenro K; Aarons L
J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
[TBL] [Abstract][Full Text] [Related]
60. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
Trials; 2011 Mar; 12():81. PubMed ID: 21418571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
